Pro: Antifibrinolytics Are Safe and Effective in Patients Undergoing Liver Transplantation

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 20, Issue 6, 2006, Pages 888-890

  Lerner, Adam B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

antifibrinolytics; aprotinin; epsilon aminocaproic acid; fibrinolysis; liver failure; liver transplantation; patient safety; thrombosis; tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; HEPATITIS B ANTIBODY; KALLIKREIN; KININ; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; GRAFT SURVIVAL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; INTRACARDIAC THROMBOSIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG EMBOLISM; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; RETRANSPLANTATION; STROKE; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOSIS;

EID: 33751351678     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2006.07.006     Document Type: Note

References (37)

1. Xia V.W., Du B., Braunfeld M., et al. Preoperative characteristics and intraoperative transfusion and vasopressor requirements in patients with low vs. high MELD scores. Liver Transpl 12 (2006) 614-620
2. Steib A., Freys G., Lehmann C., et al. Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anaesth 48 (2001) 1075-1079
3. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
4. Frasco P.E., Poterack K.A., Hentz J.G., et al. A comparison of transfusion requirements between living donation and cadaveric donation liver transplantation: Relationship to model of end-stage liver disease score and baseline coagulation status. Anesth Analg 101 (2005) 30-37
5. Spiess B.D. Choose one: Damned if you do/damned if you don't!. Crit Care Med 33 (2005) 1871-1874
6. Hebert P.C., Wells G., Blajchman M.A., et al., Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in Critical Care Investigators. N Engl J Med 340 (1999) 409-417
7. Palomo Sanchez J.C., Jimenez C., Moreno Gonzalez E., et al. Effects of intraoperative blood transfusion on postoperative complications and survival after orthotopic liver transplantation. Hepatogastroenterology 45 (1998) 1026-1033
8. Bennett-Guerrero E., Feierman D.E., Barclay G.R., et al. Preoperative and intraoperative predictors of postoperative morbidity, poor graft function, and early rejection in 190 patients undergoing liver transplantation. Arch Surg 136 (2001) 1177-1183
9. Mor E., Jennings L., Gonwa T.A., et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet 176 (1993) 219-227
10. Amin M., Fergusson D., Wilson K., et al. The societal unit cost of allogeneic red blood cells and red blood cell transfusion in Canada. Transfusion 44 (2004) 1479-1486
11. Morgan T.O. Blood conservation: The CEO perspective. J Cardiothorac Vasc Anesth 18 (2004) 15S-17S
12. Kang Y., Lewis J.H., Navalgund A., et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 66 (1987) 766-773
13. Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost 21 suppl 4 (1995) 34-44
14. Legnani C., Palareti G., Rodorigo G., et al. Protease activities, as well as plasminogen activators, contribute to the "lytic" state during orthotopic liver transplantation. Transplantation 56 (1993) 568-572
15. Porte R.J., Molenaar I.Q., Begliomini B., et al., EMSALT Study Group. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study. Lancet 355 (2000) 1303-1309
16. Findlay J.Y., Rettke S.R., Ereth M.H., et al. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: A prospective, randomized, double-blind study. Liver Transpl 7 (2001) 802-807
17. Dalmau A., Sabate A., Acosta F., et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 91 (2000) 29-34
18. Dalmau A., Sabate A., Koo M., et al. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: A comparative study. Liver Transpl 10 (2004) 279-284
19. Xia V.W., and Steadman R.H. Antifibrinolytics in orthotopic liver transplantation: Current status and controversies. Liver Transpl 11 (2005) 10-18
20. Kang Y. Clinical use of synthetic antifibrinolytic agents during liver transplantation. Semin Thromb Hemost 19 (1993) 258-261
21. Ickx B.E., van der Linden P.J., Melot C., et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. Transfusion 46 (2006) 595-605
22. Milroy S.J., Cottam S., Tan K.C., et al. Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation. Br J Anaesth 75 (1995) 747-751
23. Findlay J.Y., and Kufner R.P. Aprotinin reduces vasoactive medication use during adult liver transplantation. J Clin Anesth 15 (2003) 19-23
24. Molenaar I.Q., Begliomini B., Martinelli G., et al. Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. Anesthesiology 94 (2001) 433-438
25. Beath S.M., Nuttall G.A., Fass D.N., et al. Plasma aprotinin concentrations during cardiac surgery: Full- versus half-dose regimens. Anesth Analg 91 (2000) 257-264
26. Molenaar I.Q., Veldman M., Begliomini B., et al. Improved early graft survival in patients receiving aprotinin during orthotopic liver transplantation. Transplant Proc 33 (2001) 1345-1346
27. Baubillier E., Cherqui D., Dominique C., et al. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation 57 (1994) 1664-1666
28. Lerner A.B., Sundar E., Mahmood F., et al. Four cases of cardiopulmonary thromboembolism during liver transplantation without the use of antifibrinolytic drugs. Anesth Analg 101 (2005) 1608-1612
29. Gologorsky E., De Wolf A.M., Scott V., et al. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 7 (2001) 783-789
30. Carmassi F., Morale M., De Negri F., et al. Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis. J Mol Med 73 (1995) 89-93
31. Mammen E.F. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 6 (1992) 1247-1257
32. Bakker C.M., Metselaar H.J., Gomes M.J., et al. Intravascular coagulation in liver transplantation-Is it present or not? A comparison between orthotopic and heterotopic liver transplantation. Thromb Haemost 69 (1993) 25-28
33. Ben-Ari Z., Panagou M., Patch D., et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography. J Hepatol 26 (1997) 554-559
34. Wong W.H., Braunfeld M., and Levin P. Recurrent pulmonary embolism during liver transplantation: Possible role of hepatitis B immune globulin as a causative agent. Anesthesiology 96 (2002) 1261-1263
35. Amris C.J., and Hilden M. Anticoagulant effects of trasylol: In vitro and in vivo studies. Ann N Y Acad Sci 146 (1968) 612-624
36. Molenaar I.Q., Legnani C., Groenland T.H., et al. Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transpl 7 (2001) 896-903
37. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365